Complete Story
11/19/2025
Recent Oncology Related FDA Approvals and Expanded Indications
FDA Approves Kura Oncology Inc.’s Komzifti™ (ziftomenib) for Relapsed or Refractory Acute Myeloid Leukemia with NPM1 Mutation
FDA Approves Johnson & Johnson’s DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with High-Risk Smoldering Multiple Myeloma
FDA Approves Syndax Pharmaceutical’s Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
FDA approves GlaxoSmithKline's Blenrep (belantamab mafodotin-blmf) for Relapsed or Refractory Multiple Myeloma
More InfoReport Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
